Sign In

Adrian Rubstein

Changing BioBusiness 1% at a time

šŸ’” Bioentrepreneur | Bridging the gap for investors & startups. I help investors refine due diligence for sharper selections & guide startups on fundraising & strategic growth.

šŸ’Š Passionate about accelerating innovation in Biobusiness. I bring deep industry knowledge & a results-oriented approach to unlock potential.

šŸ™Looking to connect with visionary investors & high-growth bio startups. Let's build the future of biobusiness together!

Highlights

Apr 30Ā Ā·Ā linkedin

JP Morgan’s Biotech Leap: Covalent Magic and ADCs

Biotech investment is reaching new heights and excitement with about USD 60 B in funding in 2023 and USD + 8 B in Q1 2024. Now, a new (and big) player is making a move: JPMorgan Chase & Co.

Here“s my take on their first investment Enlaza Therapeutics

1 - JP Morgan’s Biotech Adventure: So, JP Morgan, the big financial whale, just dipped its toes into the biotech pool. šŸŒŠšŸ’°

They threw a coolĀ $100 millionĀ atĀ Enlaza Therapeutics, a company that’s all about covalent biologic platforms with a cool name WAR-LOCK (one of the most powerful characters in the Marvel Universe, coincidence?).

What’s that, you ask? This white-space technology enables, for the first time, a covalent-acting protein drug that retains the selectivity of small-format biologics. Enlaza has generated further preclinical data for its oncology drug candidates supporting the covalent mechanism of action by demonstrating efficient tumor penetration coupled with rapid systemic clearance, high tumor retention, and low off-target liabilities. šŸ¦øā€ā™‚ļøšŸ’„

2 - Why Should You Care?: JP Morgan isn’t just any investor; it’s like the Gandalf of Wall Street. When they wave their staff (or checkbook), people pay attention. šŸ§™ā€ā™‚ļøšŸ’ø

This move says, ā€œHey, biotech is where the magic happens.ā€ It’s like they’re whispering to other investors, ā€œPsst, check out this enchanted forest of protein therapeutics. It’s gonna be lit!ā€ šŸ”®šŸŒæ

3 - ADCs: The Hidden Potion: Now, let’s talk aboutĀ ADCsĀ (Antibody-Drug Conjugates). These little potions are like Cupid’s arrows, but instead of love, they deliver targeted destruction to cancer cells. šŸ¹šŸ’”

Think of them as the James Bonds of medicine—precise, lethal, and super cool. šŸ’£šŸ•¶ļø

JP Morgan’s nod to Enlaza’s covalent protein tech is like saying, ā€œHey, these ADCs might just save the world. Invest wisely, my friends!ā€ šŸŒŽšŸš€

4 - What’s in It for You?: If you’re an investor, this news is like finding a secret treasure map. šŸ—ŗļøšŸ”

Diversify your portfolio, mate! Biotech isn’t just about test tubes and lab coats anymore. It’s where dragons (read: breakthroughs) are born. šŸ‰šŸ”¬

So, grab your sword (okay, maybe just your brokerage app) and explore this enchanted forest. šŸŒ²šŸ“ˆ

Share this news with your investor buddies. They’ll thank you later. šŸ—£ļøšŸ¤

Happy to answer any specific questions you may have about the biotech investment landscape

#biotech #investment #investor #vc #drug #discovery #healthcare #market #business #patient #adc #jpmorgan #bank


Biotech investor or innovator? We assist investors unlock potential by assisting with due diligence and companies refine strategies for success and fundraising. Let's chat!

Have you enjoyed this? Recommend Repost ā™»ļø if you find it useful Follow me, hit the šŸ”” Adrian Rubstein

Related Questions

How did Adrian Rubstein develop his expertise in biobusiness and investment strategies?
What inspired Adrian Rubstein to transition from clinical research to bioentrepreneurship?
In what ways has Adrian Rubstein contributed to the acceleration of innovation in biotech?
What are some of the most significant milestones in Adrian Rubstein's career in the pharmaceutical industry?
How does Adrian Rubstein approach mentoring startups and fostering their growth in the competitive biotech landscape?
What role does Adrian Rubstein believe education plays in shaping successful bioentrepreneurs?
How has Adrian Rubstein's diverse educational background influenced his professional achievements in biobusiness?
Adrian Rubstein
AddĀ toĀ myĀ network

Experience

Founder at Ax3.Bio
Principal at CITES

Education

Designing the future, Strategy, Universidad de 'San AndrĆ©s'​
Laboratorio de Creatividad, Innovacion y Creatividad, Universidad Torcuato Di Tella
Private Equity and Venture Capital, UniversitĆ  Bocconi - Coursera
Neurology, The Omnia-Prova Education Collaborative, Inc. ("TOPEC")
Competitive Strategy, Ludwig-Maximilians-Universität München (LMU)
Gamification, University of Pennsylvania
Fundamentals of Clinical Trials, Biostatistic and Medicine, Harvard T.H. Chan School of Public Health
Epigenetic, University of Melbourne
Clinical Research Methodology, Medicine, Universidad Hospital Italiano de Buenos Aires
Clinical Trials, National Academy of Pharmacy and Biochemestry
Clinical Trials, PINCLIFA. Postgrade in Clinical and Pharmacological Research
Pharmasist, BiologĆ­a celular y molecular, University of Buenos Aires
M.Sc in Biology, Molecular and Cellular Biology, University of Buenos Aires

Location

Argentina